Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
In essence the researchers are hoping to test two separate hypotheses (described below in the
form of research questions). Therefore, the proposed analysis has been outlined according to
each hypothesis.
Hypothesis 1: Is low-dose quetiapine (50 mg/day) more effective for patients with depression
who have insomnia at treatment baseline? (Stated differently: is low-dose quetiapine 50
mg/day effective as monotherapy for patients with depression regardless of whether or not
they have insomnia at baseline?).
Hypothesis 2: Is high-dose quetiapine (150 - 300 mg/day) more effective for patients
presenting with melancholic depression at treatment baseline?